Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

CLYM vs NBP: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

CLYM Wins Head-to-Head Institutional Verdict (3–1 across 6 Pillars · 3–4 Matrix Metrics)

CLYM Overall Winner 6-Pillar Tally: CLYM 3 – 1 NBP (2 Tie) Matrix Metrics: CLYM 3 – 4 NBP

As of Nov 16, 2026, Climb Bio, Inc. (CLYM) is the stronger overall head-to-head candidate over NBP (NBP) in the Tradestie Institutional Equity Comparison Engine, winning 3–4 core matrix metrics and 3–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). CLYM carries a Unified Composite Score of 41.9/100 (SELL) at $10.00 (N/M Forward P/E, 0.0% operating margin), whereas NBP carries 51.9/100 (HOLD) at $0.79 (2.7x Forward P/E, 0.0% operating margin).

  • Composite vs. Pillar Nuance: While NBP currently prints a higher short-term Unified Composite Score (51.9/100 HOLD vs. CLYM 41.9/100 SELL), CLYM captures the overall institutional head-to-head verdict (3–4 matrix metrics and 3–1 across the 6 pillars) due to superior fundamental profitability (0.0% vs. 0.0% operating margin) and revenue trajectory (+0.0% vs. +0.0% YoY).
  • Technical & Structure Timing Caution: CLYM trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 45.5); meanwhile NBP is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 20.1). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About CLYM vs NBP
CLYM NASDAQ Head-to-Head Winner
Climb Bio, Inc. Common Stock
Pharmaceutical Preparations
$10.00
-3.47% 1D
Market Cap $638.5M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.50β · 114% Vol
Unified Composite Score
41.9 / 100 SELL
Tech 38.0 Fund 42.0 Flow 50.0 Mom 54.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 45
RSI-14: 45.5 · SMA20: $10.28 · SMA50: $11.47
NBP US Equity
NBP
Institutional Equity
$0.79
-6.66% 1D
Market Cap $96.3M
TTM Revenue N/A
Forward P/E 2.7x
Beta / 30D Vol 1.66β · 81% Vol
Unified Composite Score
51.9 / 100 HOLD
Tech 60.0 Fund 50.0 Flow 50.0 Mom 55.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -19.4%), weak momentum, RSI 20
RSI-14: 20.1 · SMA20: $1.08 · SMA50: $1.31

6-Pillar Scorecard Institutional Category Breakdown (CLYM 3 – 1 NBP)

Columns: Metric · CLYM · NBP
1. Valuation Multiples NBP
Forward P/E N/M 2.7x
Trailing P/E N/M 2.7x
PEG Ratio N/M N/M
EV / Revenue N/M N/M
2. Growth & Scale CLYM
Revenue Growth (YoY) +0.0% +0.0%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) N/A N/A
Market Cap $638.5M $96.3M
3. Profitability & Quality CLYM
Gross Margin N/A N/A
Operating Margin 0.0% 0.0%
Net Profit Margin 0.0% 0.0%
Return on Equity (ROE) -29.3% -59.1%
4. Balance Sheet & Cash Flow CLYM
Cash Generation (TTM) N/A N/A
Cash Flow Margin N/A N/A
Net Cash / Leverage $3.95 Book/Sh · -29.3% ROE $1.73 Book/Sh · -59.1% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning Tie
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile N/A (N/A) N/A (N/A)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Neutral NEUTRAL · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: CLYM (3) vs NBP (4)
Institutional Metric CLYM NBP Criterion Row Edge
Market Capitalization
Scale
$638.5M $96.3M Larger Scale CLYM
Trailing P/E Ratio
Valuation
N/M 2.7x Lower Multiple NBP
Forward P/E Ratio
Valuation
N/M 2.7x Lower Multiple NBP
Revenue Growth (YoY)
Growth
+0.0% +0.0% Higher Growth Tie
Operating Margin (TTM)
Profitability
0.0% 0.0% Higher Margin Tie
Net Profit Margin
Profitability
0.0% 0.0% Higher Margin Tie
Return on Equity (ROE)
Capital Efficiency
-29.3% -59.1% Higher ROE CLYM
52-Week Range Position
Momentum
50% ($2–$18) 0% ($1–$5) Stronger Trend CLYM
Beta / 30D Volatility
Risk Regime
1.50β · 114% Vol 1.66β · 81% Vol Lower Realized Risk NBP
Unified Institutional Score
Composite Signal
41.9 / 100 (SELL) 51.9 / 100 (HOLD) Higher Composite NBP
Trailing 12M Revenue (USD)
Operating Scale
N/A N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
N/A ($3.95 Book/Sh · -29.3% ROE) N/A ($1.73 Book/Sh · -59.1% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon CLYM +38.87 pp
CLYM: +1.83% · NBP: -37.04%
3M Horizon CLYM +15.53 pp
CLYM: -42.5% · NBP: -58.03%
6M Horizon CLYM +54.82 pp
CLYM: +1.21% · NBP: -53.61%
1Y Horizon CLYM +515.74 pp
CLYM: +434.76% · NBP: -80.98%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on CLYM vs NBP. Trailing 12-month operating profitability (CLYM 0.0% vs NBP 0.0%) and valuation multiples (CLYM N/M vs NBP 2.7x Forward P/E) are benchmarked directly in Pillar 4 below.

CLYM ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-29.3% · N/M
NBP ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-59.1% · 2.7x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
CLYM UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact CLYM Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
NBP UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact NBP Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
CLYM Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $638.5M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
NBP Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $96.3M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ CLYM vs NBP Key Questions & Quantitative Answers

As of Nov 16, 2026, Climb Bio, Inc. (CLYM) is the stronger overall head-to-head candidate over NBP (NBP) in the Tradestie Institutional Equity Comparison Engine, winning 3–4 core matrix metrics and 3–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). CLYM carries a Unified Composite Score of 41.9/100 (SELL) at $10.00 (N/M Forward P/E, 0.0% operating margin), whereas NBP carries 51.9/100 (HOLD) at $0.79 (2.7x Forward P/E, 0.0% operating margin). Composite vs. Pillar Nuance: While NBP currently prints a higher short-term Unified Composite Score (51.9/100 HOLD vs. CLYM 41.9/100 SELL), CLYM captures the overall institutional head-to-head verdict (3–4 matrix metrics and 3–1 across the 6 pillars) due to superior fundamental profitability (0.0% vs. 0.0% operating margin) and revenue trajectory (+0.0% vs. +0.0% YoY). Technical & Structure Timing Caution: CLYM trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 45.5); meanwhile NBP is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 20.1). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

CLYM leads the Growth & Scale pillar: CLYM posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with NBP at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, CLYM generates N/A in USD-normalized revenue versus N/A for NBP. In operating R&D and SG&A reinvestment, CLYM deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for NBP.

NBP screens cheaper on headline valuation multiples. CLYM trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas NBP trades at 2.7x Forward P/E, 2.7x Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against CLYM (-29.3% ROE) versus NBP (-59.1% ROE) capital efficiency.

In options market volatility and institutional positioning, CLYM carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.50β · 114% Vol realized risk). By comparison, NBP carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.66β · 81% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.